Drug Type Monoclonal antibody |
Synonyms HTI-1088, HTI-1316, SHR 1316 + [2] |
Target |
Action inhibitors |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (28 Feb 2023), |
RegulationBreakthrough Therapy (China), Special Review Project (China) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Extensive stage Small Cell Lung Cancer | China | 28 Feb 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | NDA/BLA | China | 23 Sep 2025 | |
Non-Small Cell Lung Cancer | NDA/BLA | China | 23 Sep 2025 | |
Advanced Cervical Carcinoma | Phase 3 | China | 01 Sep 2025 | |
Locally Advanced Cervical Carcinoma | Phase 3 | China | 01 Sep 2025 | |
PD-L1 positive Triple Negative Breast Cancer | Phase 3 | China | 01 Sep 2025 | |
Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 3 | China | 18 Aug 2025 | |
Muscle Invasive Bladder Carcinoma | Phase 3 | China | 25 Apr 2025 | |
Advanced Hepatocellular Carcinoma | Phase 3 | China | 28 Oct 2024 | |
Non-squamous non-small cell lung cancer | Phase 3 | China | 29 Mar 2024 | |
Non-squamous non-small cell lung cancer | Phase 3 | China | 29 Mar 2024 |
Not Applicable | Locally Advanced Unresectable Carcinoma Neoadjuvant | 9 | vadlqqpipg(kzxsyumzud) = jwamnytata nxgkamltff (hrlhubjdid ) View more | Positive | 09 Sep 2025 | ||
Phase 2/3 | 23 | azmidmsigx(ountjcwuii) = cfadrrxaem bcrdpqgcof (aaazerahwy ) View more | Positive | 03 Jul 2025 | |||
NCT04303988 (ASCO2025) Manual | Phase 2 | 35 | hbhtkeyqgh(zzvcotzmnb) = fjwivcphhp nxfetabvzb (yqfplgvyct ) View more | Positive | 30 May 2025 | ||
NCT05353361 (ASCO2025) Manual | Phase 1/2 | 50 | (In phase 1b) | dyxvpnzyoe(lnmyeveexi) = uahavhvlbh dltbwfxrdv (peacdmxoal ) | Positive | 30 May 2025 | |
(In phase 1b) | dyxvpnzyoe(lnmyeveexi) = lxemqzkeue dltbwfxrdv (peacdmxoal ) | ||||||
Phase 2 | 30 | yzdsnbwpmj(nphaqgvgse) = ksxtqvpyxg hruvlyrfro (fmsplrtvhq ) View more | Positive | 30 May 2025 | |||
Phase 2 | Recurrent Thymic Carcinoma First line | 18 | otxguahdms(fiwzxocfdi) = myhlnuwygz bfvrjfopcn (uxbpupgepn ) View more | Positive | 30 May 2025 | ||
Phase 2 | 10 | zgexdohsll(rtgpmkofct) = pjyiriiozt jxwwogfbgi (qztrukhrjw ) View more | Positive | 30 May 2025 | |||
Phase 2 | - | wtdzuwwusu(vwfizuanxw) = vwymzwejfx lkvreztuld (jhsvsywufe ) View more | - | 26 Mar 2025 | |||
Not Applicable | 75 | jqcmapygvi(qjgkkaxopb) = lebtmkhvas ooakngetdu (snmmfmmlwk, 54.8 - 77.1) View more | Positive | 26 Mar 2025 | |||
Phase 2 | 36 | Adebrelimab + Chemotherapy | idaqwdwkxn(vlmpriusqx) = apatmuwaof czhdoeyhtc (wizjfllebu, 23.1 - 56.5) View more | Positive | 23 Jan 2025 | ||
Adebrelimab + Chemotherapy (Surgery) | idaqwdwkxn(vlmpriusqx) = ndjnpyirkd czhdoeyhtc (wizjfllebu, 24.6 - 59.3) View more |